Vanda Pharmaceuticals | VNDA - Interest Expense On Debt


Vanda Pharmaceuticals reported -1.37B in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics 349.66M 12.86M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 18.84M 1.24M Jun/2026
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 10.96B 527M Jun/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Takeda JPY 63.85B 20.2B Jun/2026
Teva Pharmaceutical Industries USD 195M 21M Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Veracyte USD 2K 1000 Dec/2023